INBX
NASDAQ HealthcareInhibrx Biosciences, Inc. - Common Stock
Biotechnology
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
๐ Market Data
| Price | $73.65 |
|---|---|
| Volume | 358,697 |
| Market Cap | 1.08B |
| Beta | 3.820 |
| RSI (14-Day) | 33.2 |
| 200-Day MA | $92.16 |
| 50-Day MA | $102.89 |
| 52-Week High | $155.29 |
| 52-Week Low | $57.30 |
| Forward P/E | -8.41 |
| Price / Book | -20.45 |
๐ฏ Investment Strategy Scores
INBX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (99/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find INBX in your text
Paste any article, transcript, or post โ the tool will extract INBX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.